TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31196678

Group type: EXPERIMENTAL
Intervention: Regenerative cell-based therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phase 2 trials
Number of subjects: 0
Study: 30201691

Group type: EXPERIMENTAL
Intervention: Accelerated schedule (0, 1, and 2 months)
Number of subjects: 407

Group type: COMPARATOR
Intervention: Standard schedule (0, 1, and 6 months)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Accelerated schedule
Number of subjects: 407

Group type: COMPARATOR
Intervention: Standard schedule
Number of subjects: 407
Study: 27544829

Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy for insomnia (CBTi)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 91
Study: 25035114

Group type: EXPERIMENTAL
Intervention: Full intervention
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Partial intervention
Number of subjects: 8

Group type: COMPARATOR
Intervention: Retrospective data
Number of subjects: 8
Study: 22938651

Group type: EXPERIMENTAL
Intervention: Perfusion-cardiovascular magnetic resonance (CMR)
Number of subjects: 533

Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 533
Study: 20531094

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 60
Study: 18689590

Group type: EXPERIMENTAL
Intervention: Budesonide 200 microg/d + Formoterol 24 microg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide 800 microg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg/d + Formoterol 24 microg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Budesonide 800 microg/d vs Budesonide 200 microg/d + Formoterol 24 microg/d
Number of subjects: 0
Study: 16051518

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day (n = 14)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day plus vitamin E 400 IU/day (n = 12)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No statin or antioxidant treatment (n = 12, controls)
Number of subjects: 38
Study: 12919387

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) at a median dose of 2,400 mg/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 76
Study: 10929216

Group type: EXPERIMENTAL
Intervention: Short-term oral creatine supplementation (20 g.day‐1 for 6 days)
Number of subjects: 23
Study: 8848409

Group type: EXPERIMENTAL
Intervention: Circulating Neuropeptide Y (NPY)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Circulating Endothelin-1,2 (ET-1,2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atrial Natriuretic Peptide (ANP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma Renin Activity (PRA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aldosterone
Number of subjects: 0
Study: 1616385

Group type: EXPERIMENTAL
Intervention: Occlusive dressings and variable ambient temperature (group I)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: No dressings and variable ambient temperature (group II)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: No dressings and electromagnetic heaters (group III)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal controls (group IV)
Number of subjects: 15
Study: 6546371

Group type: EXPERIMENTAL
Intervention: Pirenzepine 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cimetidine 200 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cimetidine 400 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pirenzepine 25 mg
Number of subjects: 12
Study: 2425204

Group type: EXPERIMENTAL
Intervention: Galanin infusion at 33.2 pmol/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Galanin infusion at 7.8 pmol/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Galanin infusion (both doses)
Number of subjects: 10
Study: 29698340

Group type: EXPERIMENTAL
Intervention: Web-based lecture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional classroom lecture
Number of subjects: 0
Study: 28941361

Group type: COMPARATOR
Intervention: Repeated-mailing outreach
Number of subjects: 29340

Group type: COMPARATOR
Intervention: Electronic medical record–integrated provider best practice alert (BPA)
Number of subjects: 29340

Group type: COMPARATOR
Intervention: Direct patient solicitation
Number of subjects: 29340
Study: 28881341

Group type: EXPERIMENTAL
Intervention: Height-adjusted total kidney liver volume (hTKLV)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Height-adjusted total liver volume (hTLV)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Height-adjusted total kidney volume (hTKV)
Number of subjects: 309
Study: 26200111

Group type: EXPERIMENTAL
Intervention: Approach-Avoidance Task (AAT) where participants pulled CS+ pictures towards themselves and pushed CS- pictures away from themselves.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group underwent reversed contingencies in the AAT.
Number of subjects: 2
Study: 23982273

Group type: EXPERIMENTAL
Intervention: Oxytocin (26 IU intranasal administration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21921425

Group type: EXPERIMENTAL
Intervention: FBRA (fermented brown rice) 21.0 g/day for 2 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control food 21.0 g/day for 2 weeks
Number of subjects: 36
Study: 18513512

Group type: EXPERIMENTAL
Intervention: Ularitide 15 ng/kg per minute
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Ularitide 30 ng/kg per minute
Number of subjects: 221
Study: 16507966

Group type: EXPERIMENTAL
Intervention: Day hospital treatment
Number of subjects: 206

Group type: COMPARATOR
Intervention: Conventional in-patient care
Number of subjects: 206
Study: 11982444

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (30 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10680491

Group type: EXPERIMENTAL
Intervention: Fibroin membrane
Number of subjects: 2

Group type: COMPARATOR
Intervention: 1% SD-Ag cream
Number of subjects: 2
Study: 7667822

Group type: EXPERIMENTAL
Intervention: Clexane (enoxaparin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fragmin (dalteparin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Logiparin (tinzaparin)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UH)
Number of subjects: 12
Study: 2652887

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (Tebonin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: NaCl without drugs stimulating blood flow (Control)
Number of subjects: 15
Study: 889672

Group type: EXPERIMENTAL
Intervention: Nitrous‐oxide‐oxygen technique with neuromuscular blockage
Number of subjects: 138
Study: 29497934

Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) home visits
Number of subjects: 145

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 145
Study: 25943648

Group type: EXPERIMENTAL
Intervention: Total enterolignans (high urinary concentrations)
Number of subjects: 5179

Group type: EXPERIMENTAL
Intervention: Total isoflavones (high urinary concentrations)
Number of subjects: 5179

Group type: EXPERIMENTAL
Intervention: Daidzein (high urinary concentrations)
Number of subjects: 5179

Group type: EXPERIMENTAL
Intervention: Enterolactone (high urinary concentrations)
Number of subjects: 5179
Study: 25131978

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering treatment
Number of subjects: 67475
Study: 22882472

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET); 12 weeks of bicycle exercise training (3 × 40 min/week)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES); 12 weeks of NMES of quadriceps and calf muscles (frequency 10 Hz, mode '20 s on-20 s off,' intensity 60 mA, 2 × 60 min/day)
Number of subjects: 61
Study: 20553355

Group type: EXPERIMENTAL
Intervention: Clotrimazole (1% clotrimazole), n = 45
Number of subjects: 96

Group type: COMPARATOR
Intervention: Nystatin (100,000 IU nystatin/g + 20% zinc oxide), n = 46
Number of subjects: 96
Study: 18430210

Group type: EXPERIMENTAL
Intervention: Continuous ropivacaine 0.75% infusion
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 158
Study: 16020923

Group type: EXPERIMENTAL
Intervention: Arthos(inert) stent group (carbon-implanted surface stents)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Arthos stent group (control stents)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Arthos(inert) stent group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Arthos stent group
Number of subjects: 140
Study: 12545149

Group type: EXPERIMENTAL
Intervention: Morphine-6-glucuronide (63 to 112 mg IV bolus, followed by infusion for 1.8 to 6.4 hours)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Morphine (26 to 66 mg IV bolus, followed by infusion for 1.8 to 6.4 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 12
Study: 10626190

Group type: EXPERIMENTAL
Intervention: Nafamostat mesilate (2 mg/kg/day) administered during and after the operation for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard post-operative intensive therapies (Control)
Number of subjects: 20
Study: 7560231

Group type: EXPERIMENTAL
Intervention: 32% w/w methylene blue in a slow release device at days 0 and 28
Number of subjects: 18

Group type: COMPARATOR
Intervention: Subgingival debridement
Number of subjects: 18
Study: 2042922

Group type: EXPERIMENTAL
Intervention: Hemostagene hemostatic sheets
Number of subjects: 106

Group type: COMPARATOR
Intervention: Reference collagen sheets
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both collagen sheets
Number of subjects: 106
Study: 6928183

Group type: EXPERIMENTAL
Intervention: Pentobarbital 100 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 50
Study: 30638151

Group type: COMPARATOR
Intervention: Various cabin control systems for work shifts (randomly assigned vehicles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Demographic factors (unmarried, university degree, limited driving experience)
Number of subjects: 0
Study: 30194487

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 250

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 250
Study: 26607942

Group type: EXPERIMENTAL
Intervention: Resveratrol (500 mg twice daily)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 24813598

Group type: EXPERIMENTAL
Intervention: Solomon laser technique
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard laser technique
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Solomon laser technique (complete procedure subgroup)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard laser technique (complete procedure subgroup)
Number of subjects: 151
Study: 22670856

Group type: EXPERIMENTAL
Intervention: Autologous serum (AS) eyedrops diluted at 20%, treatment duration: 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional artificial tears, treatment duration: 2 weeks
Number of subjects: 12
Study: 20170821

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 320
Study: 18818309

Group type: EXPERIMENTAL
Intervention: anti‐CTLA‐4 antibody
Number of subjects: 6
Study: 16022747

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1.5 g daily)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 12355995

Group type: COMPARATOR
Intervention: Raloxifen
Number of subjects: 0
Study: 10648305

Group type: EXPERIMENTAL
Intervention: Group I - Avoided positive inotropic catecholamines and vasodilators; mechanical ventilation with low tidal volumes < 8 mL/kg, duration of inspiration:expiration = 3:1, peak inspiratory pressures < 18 cm H(2)O
Number of subjects: 47

Group type: COMPARATOR
Intervention: Group II - Used positive inotropic catecholamines and vasodilators; mechanical ventilation with high tidal volumes (10‐15 mL/kg) and peak inspiratory pressures up to 50 cm H(2)O
Number of subjects: 47
Study: 8551788

Group type: EXPERIMENTAL
Intervention: Leukocyte and platelet depletion using blood cell separator CS‐3000, starting immediately after the operation and ending 1 hour after aortic occlusion.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Leukocyte and platelet depletion (experimental group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no leukocyte and platelet depletion)
Number of subjects: 42
Study: 1988778

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 50 mg as an intramuscular depot injection every 3 weeks for 1 year
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Estrogen‐progestogen therapy (2 mg 17 beta‐estradiol plus 1 mg norethisterone acetate) daily for 1 year
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 79
Study: 6216814

Group type: EXPERIMENTAL
Intervention: Manipulation therapy (MTG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional therapy (CTG)
Number of subjects: 51
Study: 31860800

Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding (NAM), n = 20
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-NAM treated group, n = 20
Number of subjects: 40
Study: 31560580

Group type: EXPERIMENTAL
Intervention: CDK4/6 inhibitor and an aromatase inhibitor (AI)
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Aromatase inhibitor (AI) alone
Number of subjects: 1827
Study: 29123208

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Belatacept (BELA)
Number of subjects: 40
Study: 25491882

Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Nasal intermittent positive pressure ventilation (NIPPV) + very early surfactant treatment
Number of subjects: 59
Study: 24570029

Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 213
Study: 22313936

Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 20561180

Group type: EXPERIMENTAL
Intervention: 3 mg of melatonin daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17660178

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 0.3%/dexamethasone 0.1% (CIP/DEX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neomycin 0.35%/polymyxin B 10,000 IU/mL/hydrocortisone 1.0% (NPH)
Number of subjects: 0
Study: 15683857

Group type: EXPERIMENTAL
Intervention: 10% concentrated intravenous gammaglobulin
Number of subjects: 35

Group type: COMPARATOR
Intervention: 5% concentrated intravenous gammaglobulin
Number of subjects: 35
Study: 11866274

Group type: EXPERIMENTAL
Intervention: Lactoferrin in whole gut lavage fluid (WGLF)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Myeloperoxidase in WGLF
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Lysozyme in WGLF
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Lactoferrin in WGLF
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Stability of lactoferrin and myeloperoxidase in WGLF
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Stability of PMN-E and lysozyme in WGLF
Number of subjects: 85
Study: 10195822

Group type: EXPERIMENTAL
Intervention: Tridimensional Personality Questionnaire (TPQ)
Number of subjects: 521
Study: 8389559

Group type: EXPERIMENTAL
Intervention: Ditiocarb (DTC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 3040815

Group type: EXPERIMENTAL
Intervention: Itraconazole 50 mg before breakfast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg before breakfast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Itraconazole 50 mg with breakfast
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg with breakfast
Number of subjects: 20
Study: 28447203

Group type: COMPARATOR
Intervention: 400 µg/day folate
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 800 µg/day folate
Number of subjects: 198
Study: 27716226

Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training for staff and youth MHFA training for wider staff body
Number of subjects: 2300

Group type: EXPERIMENTAL
Intervention: Peer support service established in intervention schools
Number of subjects: 2300

Group type: COMPARATOR
Intervention: Usual practice in control schools
Number of subjects: 2300
Study: 24556095

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients
Number of subjects: 173
Study: 22982085

Group type: EXPERIMENTAL
Intervention: Capitalization approach (treatment matched to relative strengths)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Compensation approach (treatment matched to relative deficits)
Number of subjects: 34
Study: 20206314

Group type: EXPERIMENTAL
Intervention: Very-low-energy diet (VLED) (415 kcal/day)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) (810 kcal/day)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Combined groups (VLED and LED)
Number of subjects: 192
Study: 17850471

Group type: EXPERIMENTAL
Intervention: Insulin aspart (IAsp)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 26
Study: 15660025

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (4‐12 mg/d)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no candesartan)
Number of subjects: 50
Study: 12106837

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy in AMI patients
Number of subjects: 41
Study: 10433575

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.i.d.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg b.i.d.
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Clofazimine
Number of subjects: 85
Study: 9592273

Group type: EXPERIMENTAL
Intervention: New speech training method, duration 22 to 120 days (average 63 days)
Number of subjects: 50
Study: 1747286

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion (30 ng kg‐1 min‐1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion during exercise
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 14
Study: 6174041

Group type: EXPERIMENTAL
Intervention: Acebutolol, 300 mg three times daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sustained release quinidine sulfate in identical doses
Number of subjects: 20
Study: 31651299

Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy for 9 weeks
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy for 9 weeks, adherence to ≥12 treatment sessions
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy for 9 weeks, adherence to 0-11 treatment sessions
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Pre-surgery physiotherapy
Number of subjects: 197

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 197
Study: 28803710

Group type: COMPARATOR
Intervention: Intrathecal HPβCD 900 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intrathecal HPβCD 1200 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intrathecal HPβCD 600 or 900 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intrathecal HPβCD
Number of subjects: 14
Study: 25575085

Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive posterior lumbar interbody fusion (Rom-PLIF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional open posterior PLIF using freehand technique
Number of subjects: 80
Study: 24191673

Group type: EXPERIMENTAL
Intervention: Early ART (started at week 0)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Deferred ART (started when CD4 <15%)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Healthy controls (N=275)
Number of subjects: 299
Study: 21778486

Group type: EXPERIMENTAL
Intervention: 60-minute risk reduction counseling session
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20-minute HIV-STI educational session
Number of subjects: 0
Study: 18626659

Group type: EXPERIMENTAL
Intervention: Unconscious thought
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conscious thought
Number of subjects: 0
Study: 17571652

Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 20

Group type: COMPARATOR
Intervention: LASIK vs PRK
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low contrast acuity and contrast sensitivity
Number of subjects: 20
Study: 15545305

Group type: EXPERIMENTAL
Intervention: Citalopram (dosage not specified)
Number of subjects: 106
Study: 11802520

Group type: EXPERIMENTAL
Intervention: Zotepine 150 mg/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Haloperidol 9 mg/day
Number of subjects: 70
Study: 9556922

Group type: EXPERIMENTAL
Intervention: HPLC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: EMIT
Number of subjects: 30
Study: 9824170

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral group treatment (CBT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Interactional group treatment (IT)
Number of subjects: 32
Study: 2313529

Group type: EXPERIMENTAL
Intervention: Waxed dental floss
Number of subjects: 200

Group type: COMPARATOR
Intervention: Unwaxed dental floss
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Different brand of waxed dental floss
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mint flavored waxed floss
Number of subjects: 200

Group type: COMPARATOR
Intervention: Plain waxed floss
Number of subjects: 200

Group type: COMPARATOR
Intervention: Neither type of floss
Number of subjects: 200
Study: 668973

Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide (0.25 mg/cm2 of the skin)
Number of subjects: 30

Group type: COMPARATOR
Intervention: aqua distillata
Number of subjects: 30
Study: 30961875

Group type: EXPERIMENTAL
Intervention: Preparing Pequeños intervention
Number of subjects: 829

Group type: COMPARATOR
Intervention: Control group (core curriculum)
Number of subjects: 829